X0206 3 2017-12-07 0 0001714899 Denali Therapeutics Inc. DNLI 0001281933 BRATTON DOUGLAS K 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001716958 AKDL, L.P. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723842 Neuro Line Partners LP 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001626597 Crestline SI (GP), L.P. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001626596 Crestline Investors, Inc. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723787 Bratton Capital Management, L.P. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001723783 Bratton Capital Inc. 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 0001536054 Crestline Management, LP 201 MAIN STREET, SUITE 1900 FORT WORTH TX 76102 0 0 1 0 Common Stock 312500 I By AKDL, L.P. Series A-1 Convertible Preferred Stock Common Stock 14499999 I By AKDL, L.P. Series A-2 Convertible Preferred Stock Common Stock 2500000 I By AKDL, L.P. Series B-1 Convertible Preferred Stock Common Stock 1875000 I By AKDL, L.P. Series A-1 Convertible Preferred Stock Common Stock 743599 I By Neuro Line Partners, L.P. Series A-2 Convertible Preferred Stock Common Stock 128200 I By Neuro Line Partners, L.P. Series B-1 Convertible Preferred Stock Common Stock 240000 I By Neuro Line Partners, L.P. Reflects the 4-for-1 reverse stock split of the common stock and convertible preferred stock of Denali Therapeutics Inc. (the "Issuer") to be effected prior to the completion of the Issuer's initial public offering. Shares of the Issuer's Series A-1 Convertible Preferred Stock do not expire, are immediately convertible into shares of the Issuer's common stock at a one-for-one ratio and will automatically convert to shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at a one-for-one ratio. Shares of the Issuer's Series A-2 Convertible Preferred Stock do not expire, are immediately convertible into shares of the Issuer's common stock at a one-for-one ratio and will automatically convert to shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at a one-for-one ratio. Shares of the Issuer's Series B-1 Convertible Preferred Stock do not expire, are immediately convertible into shares of the Issuer's common stock at a one-for-one ratio and will automatically convert to shares of the Issuer's common stock upon the closing of the Issuer's initial public offering at a one-for-one ratio. These securities are held directly by AKDL, L.P. ("AKDL"). The general partner of AKDL is Crestline SI (GP), L.P. ("Crestline SI") and the investment manager of AKDL is Crestline Management, L.P. ("Crestline Management"). Crestline Investors, Inc. ("Crestline") is the general partner of both Crestline SI and Crestline Management. Douglas K. Bratton is the sole director of Crestline. AKDL is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by AKDL. In addition, Crestline SI and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by AKDL through direct or indirect limited partner and/or general partner interests in AKDL. (Continued from Footnote 5) Crestline SI, Crestline Management, Crestline and Mr. Bratton may each be deemed to beneficially own the securities held by AKDL. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. These securities are held directly by Neuro Line Partners, L.P. ("Neuro Line"). The general partner of Neuro Line is Bratton Capital Management, L.P. ("Bratton Capital Management"). The general partner of Bratton Capital Management is Bratton Capital, Inc. ("Bratton Capital"). Douglas K. Bratton is the sole director of Bratton Capital. Neuro Line is ultimately controlled by Mr. Bratton and Mr. Bratton has voting and investment power over all securities held by Neuro Line. In addition, Bratton Capital Management, Bratton Capital, and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line due to Bratton Capital Management's right to receive performance-based allocations and Bratton Capital Management and Mr. Bratton may be deemed to have a pecuniary interest in a portion of the securities held by Neuro Line through direct or indirect limited partner and/or general partner interests in Neuro Line. (Continued from Footnote 7) Bratton Capital Management, Bratton Capital and Mr. Bratton may each be deemed to beneficially own the securities held by Neuro Line. Each such entity and Mr. Bratton disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. DOUGLAS K. BRATTON, Name: /s/ Douglas K. Bratton 2017-12-07 AKDL, L.P., By: Crestline SI (GP), L.P., its general partner, By: Crestline Investors, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 NEURO LINE PARTNERS, L.P., By: Bratton Capital Management, L.P., its general partner, By: Bratton Capital, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 CRESTLINE SI (GP), L.P., By: Crestline Investors, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 CRESTLINE INVESTORS, INC., Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 BRATTON CAPITAL MANAGEMENT, L.P., By: Bratton Capital, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 BRATTON CAPITAL, INC., Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07 CRESTLINE MANAGEMENT, L.P., By: Crestline Investors, Inc., its general partner, Name: /s/ Douglas K. Bratton, Title: Sole Director 2017-12-07